Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Complement activation plays a central role in its pathogenesis; however, the prognostic significance of serum complement levels remains unclear. In this single-center retrospective study, we evaluated the prognostic value of serum C3, C4 levels, and C3/C4 ratio in 116 biopsy-proven primary IgAN patients with available complement measurements, followed for a median of 37.5 months. Poor prognosis was defined as a ≥ 50% decline in estimated glomerular filtration rate (eGFR) or progression to end-stage renal disease; 39 patients (33.6%) reached this endpoint. Serum C3 was significantly lower in the poor prognosis group (113.0 vs. 128.0 mg/dL, p = 0.0004), as was the C3/C4 ratio (3.39 vs. 4.27, p = 0.0009), while serum C4 did not differ significantly (p = 0.520). ROC analysis identified serum C3 (AUC = 0.703, 95% CI: 0.595–0.801, cutoff 121.1 mg/dL) and C3/C4 ratio (AUC = 0.689, 95% CI: 0.575–0.791, cutoff 3.62) as significant predictors. Bootstrap validation confirmed cutoff robustness (C3: 97.0–144.0 mg/dL; C3/C4: 3.03–4.31). Kaplan–Meier analysis demonstrated significantly worse renal survival with low C3 (p = 0.011) and low C3/C4 ratio (p = 0.001). Serum C3 correlated with tubular atrophy score (r = −0.197, p = 0.036) and C3/C4 ratio with crescent score (r = −0.272, p = 0.003). In expanded multivariate Cox regression, ACE inhibitor/ARB use was independently associated with better prognosis (HR = 0.136, 95% CI: 0.031–0.605, p = 0.009). Serum C3 and C3/C4 ratio at diagnosis are associated with renal prognosis and histopathological severity in IgAN and may serve as adjunctive prognostic markers alongside established parameters.
Sezer et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: